<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37773184</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.</ArticleTitle><Pagination><StartPage>145</StartPage><MedlinePgn>145</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-023-00739-2</ELocationID><Abstract><AbstractText>Epstein-Barr virus (EBV) reactivation may be involved in long-COVID symptoms, but reactivation of other viruses as a factor has received less attention. Here we evaluated the reactivation of parvovirus-B19 and several members of the Herpesviridae family (DNA viruses) in patients with long-COVID syndrome. We hypothesized that monovalent COVID-19 vaccines inhibit viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, thereby reducing clinical symptoms. Clinical and laboratory data for 252 consecutive patients with PCR-verified past SARS-CoV-2 infection and long-COVID syndrome (155 vaccinated and 97 non-vaccinated) were recorded during April 2021-May 2022 (median 243 days post-COVID-19 infection). DNA virus-related IgG and IgM titers were compared between vaccinated and non-vaccinated long-COVID patients and with age- and sex-matched non-infected, unvaccinated (pan-negative for spike-antibody) controls. Vaccination with monovalent COVID-19 vaccines was associated with significantly less frequent fatigue and multiorgan symptoms (p&#x2009;&lt;&#x2009;0.001), significantly less cumulative DNA virus-related IgM positivity, significantly lower levels of plasma IgG subfractions 2 and 4, and significantly lower quantitative cytomegalovirus IgG and IgM and EBV IgM titers. These results indicate that anti-SARS-CoV-2 vaccination may interrupt viral cross-talk in patients with long-COVID syndrome (ClinicalTrials.gov Identifier: NCT05398952).</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gy&#xf6;ngy&#xf6;si</LastName><ForeName>Mariann</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7083-2107</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. mariann.gyongyosi@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukovic</LastName><ForeName>Dominika</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8040-8086</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mester-Tonczar</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1426-6670</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlabinger</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Einzinger</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Information Systems Engineering, Research Unit of Information and Software Engineering, Vienna University of Technology, 1040, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spannbauer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9819-0361</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweiger</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schefberger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2890-9366</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samaha</LastName><ForeName>Eslam</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Klinik Donaustadt, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergler-Klein</LastName><ForeName>Jutta</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2591-1380</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riesenhuber</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5061-7354</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsche</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hengstenberg</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucher</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0704-0940</Identifier><AffiliationInfo><Affiliation>Biobank, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haslacher</LastName><ForeName>Helmuth</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4605-2503</Identifier><AffiliationInfo><Affiliation>Biobank, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuer</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strassl</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puchhammer-St&#xf6;ckl</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loewe</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beitzke</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3179-3827</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hasimbegovic</LastName><ForeName>Ena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7544-7972</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zelniker</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-6444-8598</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05398952</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>KLI 876</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no financial or non-financial competing interest. M.G. has received honoraria for long-COVID lectures from the following companies: General Reinsurance AG, Genericon Pharma, and &#xd6;sterreichische Apotheker-Verlagsgesellschaft m.b.H.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>12</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37773184</ArticleId><ArticleId IdType="pmc">PMC10541897</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00739-2</ArticleId><ArticleId IdType="pii">10.1038/s41541-023-00739-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med. Hypotheses. 2021;149:110538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatayama Y, Hashimoto Y, Motokura T. Frequent co-reactivation of Epstein-Barr virus in patients with cytomegalovirus viremia under immunosuppressive therapy and/or chemotherapy. J. Int. Med. Res. 2020;48:300060520972880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7708703</ArticleId><ArticleId IdType="pubmed">33249964</ArticleId></ArticleIdList></Reference><Reference><Citation>Libert N, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed. J. 2015;38:70&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">25179711</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, et al. Recent advances in HBV reactivation research. Biomed. Res. Int. 2018;2018:2931402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327272</ArticleId><ArticleId IdType="pubmed">30687740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner GF, et al. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit. Care. 2020;24:657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci. Rep. 2021;11:10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Granda MJ, et al. Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: a point prevalence study in a general hospital. Rev. Esp. Quimioter. 2023;36:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910675</ArticleId><ArticleId IdType="pubmed">36408974</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui SS, et al. Cytomegalovirus coinfection in critically ill patients with novel Coronavirus-2019 disease: pathogens or spectators? Indian J. Crit. Care Med. 2022;26:376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015933</ArticleId><ArticleId IdType="pubmed">35519914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuest KE, et al. Risk factors for Herpes simplex virus (HSV) and Cytomegalovirus (CMV) infections in critically-ill COVID-19 patients. Multidiscip. Respir. Med. 2022;17:815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941339</ArticleId><ArticleId IdType="pubmed">35340709</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect. Dis. Now. 2021;51:296&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, &#x2212;7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J. Med. Virol. 2021;93:1850&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537064</ArticleId><ArticleId IdType="pubmed">32970319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Muras A, et al. Bilateral facial nerve palsy associated with COVID-19 and Epstein-Barr virus co-infection. Eur. J. Neurol. 2021;28:358&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537085</ArticleId><ArticleId IdType="pubmed">32997868</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2021;104:315&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Galestanian A, Suthar KH, Karnath B. Immune thrombocytopenic purpura in a patient with SARS-CoV-2 and Epstein-Barr virus. Cureus. 2021;13:e13615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011470</ArticleId><ArticleId IdType="pubmed">33816014</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncati L, Lusenti B, Nasillo V, Manenti A. Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease. Ann. Hematol. 2020;99:1945&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245576</ArticleId><ArticleId IdType="pubmed">32447425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrhofer J, et al. Association between Epstein-Barr-Virus reactivation and development of Long-COVID fatigue. Allergy. 2023;78:297&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538037</ArticleId><ArticleId IdType="pubmed">35950630</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling. Preprint at medRxiv10.1101/2022.08.09.22278592 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AVW, Guy GW, Botchway SW, Bell JD. SARS-CoV-2 and EBV; the cost of a second mitochondrial &#x201c;whammy&#x201d;? Immun. Ageing. 2021;18:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556816</ArticleId><ArticleId IdType="pubmed">34717676</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 2023;133:e163669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D, Church TM, Swaminathan S. Epstein-Barr virus lytic replication induces ACE2 expression and enhances SARS-CoV-2 pseudotyped virus entry in epithelial cells. J. Virol. 2021;95:e0019221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316011</ArticleId><ArticleId IdType="pubmed">33853968</ArticleId></ArticleIdList></Reference><Reference><Citation>Meskill SD, O&#x2019;Bryant SC. Respiratory virus co-infection in acute respiratory infections in children. Curr. Infect. Dis. Rep. 2020;22:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223550</ArticleId><ArticleId IdType="pubmed">31980966</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Fowlkes AL, Steffens A, Finelli L, Cowling BJ. Assessment of virus interference in a test-negative study of influenza vaccine effectiveness. Epidemiology. 2017;28:514&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535302</ArticleId><ArticleId IdType="pubmed">28362642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, et al. Differences in long-COVID symptoms between vaccinated and non-vaccinated (BNT162b2 vaccine) hospitalized COVID-19 survivors infected with the Delta variant. Vaccines (Basel) 2022;10:1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504977</ArticleId><ArticleId IdType="pubmed">36146560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera JE, et al. Response to letter to the editor regarding &#x201c;Multi-Disciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in patients with Post-Acute sequelae of SARS-CoV-2 infection (PASC)&#x201d;. PM R. 2021;13:1439&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662053</ArticleId><ArticleId IdType="pubmed">34617402</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah YS, et al. An algorithm for ramp up of ophthalmic elective surgeries post-COVID-19. Ophthalmic Epidemiol. 2021;28:90&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">33050755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyongyosi M, et al. Long COVID and the cardiovascular system &#x2013; elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial &amp; Pericardial Diseases. Cardiovasc Res. 2022;119:336&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384470</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Riesenhuber M, et al. Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria. BMJ Open. 2023;13:e063760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9852740</ArticleId><ArticleId IdType="pubmed">36657754</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslacher H, et al. Usage data and scientific impact of the prospectively established fluid bioresources at the hospital-based MedUni Wien Biobank. Biopreserv Biobank. 2018;16:477&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6308288</ArticleId><ArticleId IdType="pubmed">30335475</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper FP, Spahlinger T, Zhou L. Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease. J. Infect. 2011;63:260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153592</ArticleId><ArticleId IdType="pubmed">21546090</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler K, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022;22:1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9435408</ArticleId><ArticleId IdType="pubmed">36050659</ArticleId></ArticleIdList></Reference><Reference><Citation>Naendrup JH, et al. Reactivation of EBV and CMV in severe COVID-19-epiphenomena or trigger of hyperinflammation in need of treatment? A large case series of critically ill patients. J. Intensive Care Med. 2022;37:1152&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396115</ArticleId><ArticleId IdType="pubmed">34791940</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods CR. False-positive results for immunoglobulin M serologic results: explanations and examples. J. Pediatr. Infect. Dis. Soc. 2013;2:87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26619450</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014;5:520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang P, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023;8:eade2798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C, Tang YD, Xu G, Zheng C. The crosstalk between viral RNA- and DNA-sensing mechanisms. Cell Mol. Life Sci. 2021;78:7427&#x2013;7434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554519</ArticleId><ArticleId IdType="pubmed">34714359</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif MB, Raja R, Kessler PM, Sen GC. Relative contributions of the cGAS-STING and TLR3 signaling pathways to attenuation of Herpes Simplex Virus 1 replication. J. Virol. 2020;94:e01717&#x2013;e01719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158705</ArticleId><ArticleId IdType="pubmed">31896590</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstein, R. et al. Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data. Preprint at medRxiv10.1101/2022.02.04.22270474 (2022).</Citation></Reference><Reference><Citation>Hebert-Dufresne L, Althouse BM. Complex dynamics of synergistic coinfections on realistically clustered networks. Proc. Natl Acad. Sci. USA. 2015;112:10551&#x2013;10556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547298</ArticleId><ArticleId IdType="pubmed">26195773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff GG. Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season. Vaccine. 2020;38:350&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126676</ArticleId><ArticleId IdType="pubmed">31607599</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavada J, Dixon WG, Askling J, Registers ESGOLO, Drug S. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann. Rheum. Dis. 2014;73:628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24058015</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyongyosi M, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc. Res. 2023;119:336&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384470</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir. Med. 2022;10:715&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>